Comparative study of the influence of proteasome inhibitor MG132 and ganciclovir on the cytomegalovirus-specific CD8 + T-cell immune response

Viral Immunology

Volumn 24, Issue 6, 2011, Pages 455-461

  Wang, Yanjun ^a,b   Sun, Bin ^b   Volk, Hans Dieter ^a   Proesch, Susanna ^a   Kern, Florian ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GAMMA INTERFERON; GANCICLOVIR;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; REVIEW; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE PROTEINASE INHIBITORS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GANCICLOVIR; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LEUPEPTINS; VIRUS ACTIVATION; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 83255176112     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0038     Document Type: Review

References (30)

1. Reddehase MJ: The immunogenicity of human and murine cytomegaloviruses. Curr Opin Immunol 2000;12:738.
2. Tu W, Potena L, Stepick-Biek P, et al.: T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006;114:1608-1615. (Pubitemid 44547431)
3. Eid AJ, Brown RA, Hogan WJ, et al.: Kinetics of interferongamma producing cytomegalovirus (CMV)-specific CD4+ and CD8 + T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009;11:519-528.
4. Cummins NW, Deziel PJ, Abraham RS, and Razonable RR: Deficiency of cytomegalovirus (CMV)-specific CD8 + T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl Infect Dis 2009;11:20-27.
5. Sund F, Lidehall AK, Claesson K, et al.: CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplant 2010;24:401-409.
6. Kagi D, Vignaux F, Ledermann B, et al.: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-530. (Pubitemid 24264998)
7. Walker JD, Maier CL, and Pober JS: Cytomegalovirusinfected human endothelial cells can stimulate allogeneic CD4 + memory T cells by releasing antigenic exosomes. J Immunol 2009;182:1548-1559.
8. Isada CM, Yen-Lieberman B, Lurain NS, et al.: Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 2002;4:189-194. (Pubitemid 36142804)
9. Alain S, Hantz S, Scieux C, et al.: Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. J Med Virol 2004;73:566-573. (Pubitemid 38857207)
10. Prichard MN, and Kern ER: The search for new therapies for human cytomegalovirus infections. Virus Res 2010;157: 212-221.
11. Lurain NS, Bhorade SM, Pursell KJ, et al.: Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002;186:760-768. (Pubitemid 35013427)
12. Reddehase MJ, Podlech J, and Grzimek NK: Mouse models of cytomegalovirus latency: overview. J Clin Virol 2002;25 Suppl 2:S23-S36. (Pubitemid 35287189)
13. Reddehase MJ: Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002;2:831-844. (Pubitemid 37328706)
14. Shimamura M, Murphy-Ullrich JE, and Britt WJ: Human cytomegalovirus induces TGF-beta1 activation in renal tubular epithelial cells after epithelial-to-mesenchymal transition. PLoS Pathog 20106:e1001170.
15. Kuijpers TW, Vossen MT, Gent MR, et al.: Frequencies of circulating cytolytic, CD45RA + CD27-, CD8 + T lymphocytes depend on infection with CMV. J Immunol 2003;170: 4342-4348. (Pubitemid 36428204)
16. Sierro S, Rothkopf R, and Klenerman P: Evolution of diverse antiviral CD8 + T cell populations after murine cytomegalovirus infection. Eur J Immunol 2005;35:1113-1123. (Pubitemid 40542218)
17. Tormo N, Solano C, Benet I, et al.: Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8 + and CD4 + T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. J Med Virol 2010;82:1208-1215.
18. Naeger DM, Martin JN, Sinclair E, et al.: Cytomegalovirusspecific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010; 5:e8886.
19. Hebart H, Rauser G, Stevanovic S, et al.: A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation. Exp Hematol 2003;31:966-973. (Pubitemid 37211382)
20. Weekes MP,Wills MR,Mynard K, et al.: The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J Virol 1999; 73:2099-2108. (Pubitemid 29098114)
21. Prosch S, Priemer C, Hoflich C, et al.: Proteasome inhibitors: a novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation. Antivir Ther 2003; 8:555-567. (Pubitemid 38057101)
22. Roden MM, Lee KH, Panelli MC, and Marincola FM: A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods 1999;226:29-41. (Pubitemid 29336528)
23. Blanco B, Sanchez-Abarca LI, Caballero-Velazquez T, et al.: Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens. Leuk Res 2011;35:1412-1415.
24. Loureiro J, and Ploegh HL: Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv Immunol 2006;92:225-305. (Pubitemid 44834531)
25. Kikkert M, Hassink G, Barel M, et al.: Ubiquitination is essential for human cytomegalovirus US11-mediated dislocation of MHC class I molecules from the endoplasmic reticulum to the cytosol. Biochem J 2001;358:369-377. (Pubitemid 32826353)
26. Kim HJ, Joo HJ, Kim YH, et al.: Systemic analysis of heat shock response induced by heat shock and a proteasome inhibitor MG132. PLoS One 2011;6:e20252.
27. Kaspari M, Tavalai N, Stamminger T, et al.: Proteasome inhibitor MG132 blocks viral DNA replication and assembly of human cytomegalovirus. FEBS Lett 2008;582:666-672.
28. Driscoll JJ, and Dechowdhury R: Therapeutically targeting the SUMOylation, ubiquitination and proteasome pathways as a novel anticancer strategy. Target Oncol 2010;5:281-289.
29. Basler M, Dajee M, Moll C, et al.: Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010;185:634-641.
30. Groettrup M, Kirk CJ, and Basler M: Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 2010; 10:73-78.